Biosimilar EBITDA margin
28%
+700bps YoY
Biosimilar EBITDA margin expanded to 28% in Q3, up from 21% a year ago, driven by favorable product and geographic mix.
BIOCON
Other
10 Feb 2026
Biocon Limited — Q3 FY26
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and generics growth of 24%.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and generics growth of 24%. The biosimilar business prioritized high-margin markets, boosting profitability, while generics benefited from liraglutide launches in Europe. Management highlighted that major capex is behind, with annualized interest savings of ₹300 crore expected from FY27. The merger of Biocon Biologics into Biocon is on track, creating an integrated platform. Key risks include the CRDMO segment's continued weakness due to a single customer issue and regulatory uncertainty around GLP-1 approvals in Canada.
Key Numbers
Generics revenue growth
24%
+24% YoY
Generics revenue grew 24% YoY to ₹851 crore, supported by liraglutide launches in Europe and improved formulations business.
Net debt-to-EBITDA
<2.5x
down from ~4x
Net debt-to-EBITDA improved to below 2.5x after retiring ~$600M of structured debt over the past two quarters.
Biosimilar PBT
>₹100 crore
3rd consecutive quarter
Biosimilar profit before tax exceeded ₹100 crore for the third consecutive quarter, reflecting sustained profitability improvement.
Management Guidance
Annualized interest savings of ~₹300 crore from FY27
Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.
Management guidance marginsBiosimilar EBITDA margin to be in mid-20s for full year FY26
Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.
Management guidance marginsCapex to moderate to <$225 million and further decline
Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.
Management guidance capexInsulin drug product capacity to double in FY27
The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.
Management guidance expansionKey Risks
CRDMO segment weakness due to single customer issue
CRDMO revenue declined 3% YoY due to challenges with one customer, and management acknowledged the pressure will take time to ease.
medium · management_commentaryRegulatory uncertainty for GLP-1 generics in Canada
Health Canada has not approved any generic GLP-1, including liraglutide, due to unclear regulatory requirements, delaying semaglutide launch.
medium · analyst_questionPotential erosion of legacy biosimilar revenues
Management noted that while new launches drive growth, legacy products may face erosion, which could offset some gains.
low · management_commentaryCompetitive pressure from innovator GLP-1 formulations
Novo Nordisk's potential launch of a different formulation (e.g., oral) could impact generic GLP-1 market dynamics.
medium · analyst_questionNotable Quotes
Q3 FY26 represents an important operational inflection point for Biocon. With major capex now largely behind us and operating leverage beginning to play out, we are progressing from a phase of balance sheet resilience into a cycle of sustainable growth, margin expansion and a cash flow-led value creation.
We've refrained from giving specific guidance for the future... but clearly the future is more exciting than what the past is, is a fair way to look at it.
We have four molecules in the zone of $200 million annualized revenues and adalimumab was one of that.
Frequently Asked Questions
What was Biocon's revenue in Q3 FY26?
Biocon reported revenue of ₹4,173 Cr in Q3 FY26, representing a +9% change compared to the same quarter last year.
What guidance did Biocon management give for FY27?
Annualized interest savings of ~₹300 crore from FY27: Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt. Biosimilar EBITDA margin to be in mid-20s for full year FY26: Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%. Capex to moderate to <$225 million and further decline: Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes. Insulin drug product capacity to double in FY27: The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.
What are the key risks for Biocon in FY27?
Key risks include CRDMO segment weakness due to single customer issue — CRDMO revenue declined 3% YoY due to challenges with one customer, and management acknowledged the pressure will take time to ease.; Regulatory uncertainty for GLP-1 generics in Canada — Health Canada has not approved any generic GLP-1, including liraglutide, due to unclear regulatory requirements, delaying semaglutide launch.; Potential erosion of legacy biosimilar revenues — Management noted that while new launches drive growth, legacy products may face erosion, which could offset some gains.; Competitive pressure from innovator GLP-1 formulations — Novo Nordisk's potential launch of a different formulation (e.g., oral) could impact generic GLP-1 market dynamics..
Did Biocon meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Biocon Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.